Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRAS | P01112 | 14/20 | 0.56 |
| ▸ | ESR1 | P03372 | 13/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 13/20 | 0.56 |
| ▸ | TOP1 | P11387 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brostallicin SCHEMBL3678233 | 1.00 | HRAS (0.56) | HRASESR1ESR2TOP1KDM4E | |
| Brostallicin SCHEMBL2230670 | 0.99 | KDM4E (0.57) | HRASESR1ESR2TOP1KDM4E | |
| Hydrochloric Acid SCHEMBL5445158 | 0.99 | KDM4E (0.57) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL3681393 | 0.96 | HRAS (0.54) | HRASESR1ESR2TOP1KDM4E | |
| Hydrochloric Acid SCHEMBL3454055 | 0.95 | KDM4E (0.55) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL6779962 | 0.91 | HRAS (0.48) | HRASESR1ESR2TOP1KDM4E | |
| Hydrochloric Acid SCHEMBL3455112 | 0.91 | KDM4E (0.50) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL7541678 | 0.91 | HRAS (0.53) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL6776283 | 0.91 | HRAS (0.48) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL3672404 | 0.90 | HRAS (0.70) | HRASESR1ESR2TOP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030023031-A1 | Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents | PHARMACIA & UPJOHN S.P.A. | 2003-01-30 | — | — | US | claimed |
| US-6482920-B1 | Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents | PHARMACIA ITALIA, S.P.A. (IT) | 2002-11-19 | — | — | US | claimed |
| EP-0915845-B1 | ACRYLOYL SUBSTITUTED DISTAMYCIN DERIVATIVES, PROCESS FOR PREPARING THEM, AND THEIR USE AS ANTITUMOR AND ANTIVIRAL AGENTS | PHARMACIA & UPJOHN SPA (IT) | 2001-09-12 | — | — | EP | claimed |
| US-20030023031-A1 | Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents | PHARMACIA & UPJOHN S.P.A. | 2003-01-30 | — | — | US | disclosed |
| US-6482920-B1 | Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents | PHARMACIA ITALIA, S.P.A. (IT) | 2002-11-19 | — | — | US | disclosed |
| EP-0915845-B1 | ACRYLOYL SUBSTITUTED DISTAMYCIN DERIVATIVES, PROCESS FOR PREPARING THEM, AND THEIR USE AS ANTITUMOR AND ANTIVIRAL AGENTS | PHARMACIA & UPJOHN SPA (IT) | 2001-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030023031-A1 | Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents | EIF2AK2, ACR, EIF4A1 | HRAS 399/4885ESR1 3985/4885ESR2 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.